Mesa Laboratories Retained Earnings (Accumulated Deficit) 2010-2024 | MLAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mesa Laboratories retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Mesa Laboratories Retained Earnings (Accumulated Deficit) 2010-2024 | MLAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$233.1B
Intuitive Surgical (ISRG)	$171.3B
Alcon (ALC)	$47.7B
IQVIA Holdings (IQV)	$44.2B
IDEXX Laboratories (IDXX)	$42.1B
Edwards Lifesciences (EW)	$40.7B
DexCom (DXCM)	$27.8B
STERIS (STE)	$23.5B
SONOVA HOLDING (SONVY)	$20.8B
Waters (WAT)	$19.8B
Hologic (HOLX)	$19B
Sysmex ADR (SSMXY)	$12.3B
Fresenius Medical Care AG KGaA (FMS)	$12.2B
Teleflex (TFX)	$11.4B
Globus Medical (GMED)	$9.4B
Penumbra (PEN)	$7.6B
Glaukos (GKOS)	$6.7B
Masimo (MASI)	$6.1B
TransMedics (TMDX)	$5.2B
PROCEPT BioRobotics (PRCT)	$4.3B
Integer Holdings (ITGR)	$4.3B
Tandem Diabetes Care (TNDM)	$2.8B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.6B
Inari Medical (NARI)	$2.6B
Elekta AB (EKTAY)	$2.6B
Nihon Kohden (NHNKY)	$2.5B
RxSight (RXST)	$2B
Integra LifeSciences Holdings (IART)	$1.4B
Pulse Biosciences (PLSE)	$1.2B